Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CHMP Recommends Approval of Legend’s CAR-T as Second-Line Multiple Myeloma Therapy

publication date: Feb 23, 2024

Legend Biotech reported Europe’s CHMP recommended approval of its lead CAR-T drug, Carvykti®, for a new indication: second-line therapy for adult patients with relapsed and refractory multiple myeloma. Carvykti® (ciltacabtagene autoleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy. It is currently indicated to treat adult M/M patients as a fifth-line therapy. The filing was conducted by a subsidiary of Janssen, Legend’s partner on the drug. Legend was spun out of Nanjing’s GenScript, though it now lists Somerset, NJ as its global headquarters while continuing to operate in Nanjing as well. More details...

Stock Symbol: (NSDQ: LEGN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital